Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

By Lauren Vagnone | July 9, 2018

Acquisition strengthens BioIVT’s transporter sciences capabilities and enables it to partner with customers on new drug applications and mechanistic studies related to transporters.

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.

Read more

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

By Lauren Vagnone | June 28, 2018

Research using BioIVT’s TRANSPORTER CERTIFIED™ hepatocytes in sandwich culture and HEPATOPAC® technology in vitro liver models will be presented.

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.

Read more

BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions

By Lauren Vagnone | June 6, 2018

These in vitro models can help to identify herbal ingredients with the potential to alter the safety or efficacy of prescription drugs.

BioIVT, a leading provider of biospecimens and related services, today announced that it will be hosting a webinar entitled “Whole-cell In Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions (HDIs)” at 11 am ET on June 20.
Read more

BioIVT Granted Human Tissue Authority License for a Second UK Site

By Lauren Vagnone | May 31, 2018

HTA licenses help verify that BioIVT biospecimens meet the highest quality standards.

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that the Human Tissue Authority (HTA) has granted a satellite license to its West Sussex facility.
Read more

BioIVT Appoints Steven W. Louie as Director of Transporter Sciences

By Lauren Vagnone | May 9, 2018

BioIVT continues to expand capabilities in its ADME Tox Research Services Group

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that Steven W. Louie has joined the company as Director of Transporter Sciences. In his new role, Louie will lead the expansion of BioIVT’s hepatic transporter business.

Read more

BioIVT to Discuss In Vitro Hepatic Models for Toxicity Studies at the AAPS Joint Workshop on Drug Transporters in ADME

By Lauren Vagnone | April 16, 2018

BioIVT will also showcase its hepatocyte products and micropatterned co-culture liver models

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be participating in two sessions at the American Association of Pharmaceutical Scientists (AAPS) Joint Workshop on Drug Transporters in ADME: From The Bench To The Bedside. This event will be held from Apr. 16-18 at the Hyatt Regency Dulles in Herndon, VA.
Read more

BioIVT to Discuss Best Practices for Assessing T Cell-mediated Cytotoxicity at the AACR Annual Meeting

By Lauren Vagnone | April 12, 2018

BioIVT will present a workshop and two poster sessions, and also exhibit at this year’s conference

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be making several scientific contributions to the Society of Toxicology (SOT) 57th Annual Meeting and ToxExpo. This event will be held from Mar. 11-15 at the Henry B. González Convention Center in San Antonio, Texas.
Read more

BioIVT Acquires Ascendance Biotechnology, Expanding its Drug Safety Testing and Toxicology Portfolios

By Lauren Vagnone | March 27, 2018

BioIVT now offers unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it has acquired Ascendance Biotechnology, Inc. Ascendance was formed in November 2015 from the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. to form a multinational cell-based assay company.

As a result, BioIVT is adding Hepregen’s HepatoPac®, HepatoMune™ and HepatoStem™ liver cell and stem cell product lines to its drug safety testing and toxicology portfolios…
Read more

BioIVT Highlights Advances in Assessing a Drug Candidate’s Risk of Producing Liver Damage at the Society of Toxicology Annual Meeting and ToxExpo

By Lauren Vagnone | March 12, 2018

BioIVT will present a workshop and two poster sessions, and also exhibit at this year’s conference

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be making several scientific contributions to the Society of Toxicology (SOT) 57th Annual Meeting and ToxExpo. This event will be held from Mar. 11-15 at the Henry B. González Convention Center in San Antonio, Texas.
Read more

BioIVT Launches New Website, Highlighting Expanded Biospecimen Product and Service Portfolios for Drug Development Researchers

By Lauren Vagnone | March 4, 2018

Website also sports new scientific resources, streamlined navigation, and enhanced search functionality.

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced the launch of its comprehensive, new, user-friendly website at www.bioivt.com. This launch coincides with the introduction of BioIVT’s new logo and marks the culmination of its new brand rollout.

“BioIVT has greatly expanded its product and service portfolios during the past few months with its acquisitions of Asterand Bioscience™ and Qualyst Transporter Solutions in August 2017 and September, 2017, respectively,” said Courtney Noah, PhD, BioIVT Vice President of Marketing. “We developed this new company website to share our vision, display our entire range of biospecimen and value-added service offerings in one place, and demonstrate new ways in which we can partner with drug researchers to elevate science.” …
Read more